Alexandria Real Estate Equities Inc(ARE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | - | EPS (ttm) | -8.42 | Insider Own | 2.38% | Shs Outstand | 170.8M | Perf Week | -5.56% |
| Market Cap | 6.95B | Forward P/E | - | EPS next Y | -210.48% | Insider Trans | 0.23% | Shs Float | 170.0M | Perf Month | -17.66% |
| Enterprise Value | 23.41B | PEG | - | EPS next Q | -0.11 | Inst Own | 99.2% | Short Float | 4.27% | Perf Quarter | -23.97% |
| Income | -1.44B | P/S | 2.52 | EPS this Y | 109.22% | Inst Trans | 3.32% | Short Ratio | 3.36 | Perf Half Y | -2.78% |
| Sales | 2.76B | P/B | 0.46 | EPS next 5Y | 50.22% | ROA | -4.02% | Short Interest | 7.26M | Perf YTD | -18.45% |
| Book/sh | 86.67 | P/C | 13.53 | EPS past 3/5Y | - | ROE | -9.13% | 52W High | -42.81% ($69.78) | Perf Year | -36.59% |
| Cash/sh | 2.95 | P/FCF | 5.85 | Sales past 3/5Y | 5.34% 9.93% | ROIC | -5.16% | 52W Low | 1.27% ($39.41) | Perf 3Y | -56.46% |
| Dividend Est. | $2.88 (7.22%) | EV/EBITDA | 11.89 | EPS Y/Y TTM | -240.78% | Gross Margin | 22.87% | Volatility(W/M) | 4.92% 3.88% | Perf 5Y | -80.29% |
| Dividend TTM | 2.88 | EV/Sales | 8.48 | Sales Y/Y TTM | -9.86% | Oper. Margin | 26.54% | ATR (14) | 1.82 | Perf 10Y | -61.31% |
| Dividend Ex-Date | 2026/9/30 | Quick Ratio | 1.65 | EPS Q/Q | -170.85% | Profit Margin | -52.01% | RSI (14) | 31.14 | Recom | 3.29 |
| Dividend Gr. 3/5Y | -0.28% 1.99% | Current Ratio | 1.65 | Sales Q/Q | -10.74% | SMA20 | -8.46% ($43.6) | Beta | 1.17 | Target Price | $51 |
| Payout | - | Debt/Eq | 0.9 | Earnings | 2026/10/26 | SMA50 | -17.8% ($48.55) | Rel Volume | 2.6 | Prev Close | $40.86 |
| Employees | 514 | LT Debt/Eq | 0.88 | EPS/Sales Surpr. | -13401.81% 3.86% | SMA200 | -19.69% ($49.69) | Avg Volume(3M) | 2.16M | Price | $39.91 |
| IPO | 1997/5/23 | Option/Short | Yes/Yes | Trades | 32491 | Volume | 5,600,813 | Change | -2.33% |
A US office-focused REIT that owns and leases laboratory and office space tailored for life sciences and biotechnology tenants. Its performance is driven by demand from biotech tenants and interest rate trends.
Over the past 1 year, on the lower side
43% below its 1-year high.
Traded more than usual. That is 260% of its average volume.
ARE keeps an operating profit but posts a net loss
Of every $100 in sales, $26.54 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +109.2% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $252. Peers typically go for $224. Compared with its own 4-year average, it is 1603% pricier now.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -80.3%. The S&P 500 did +69% over the same period.
Tap to view numbers
Dividends are paid consistently
Pays 7.22% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 99.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
It ranks #4 of 20 in the industry
Based on market cap of $7B.
FAQ
What kind of company is ARE?
ARE belongs to the Real Estate sector and operates in the REIT - Office industry.
What is the market cap of ARE?
The market cap of ARE is approximately $7.0B, ranking 1,140 within its sector.
Does ARE pay dividends?
ARE has a dividend yield of approximately 7.22%, with an annual dividend of $2.88.
What is the 52-week high and low for ARE?
ARE has recorded a 52-week high of $69.78 and a low of $39.41.